FDA½ÓÊÜng28ÄϹ¬Ìá½»µÄÔö²¹ÉúÎïÖƼÁÐí¿ÉÉêÇ룬²¢ÊÚÓèLEQEMBI?¹Å°åÉóÅúÓÅÏÈÉóÆÀ×ʸñ

FDA½«ÆÀ¹ÀÑéÖ¤ÐÔIIIÆÚClarity ADÊý¾Ý£¬ÒÔÈ·¶¨ÊÇ·ñ½«LEQEMBI?µÄ¼ÓËÙÉóÅúת»»Îª¹Å°åÉóÅú

ÓÅÏÈÉóÆÀ½«ÓÚ2023Äê7ÔÂ6ÈÕͨ¹ý¡¶´¦·½Ò©Ê¹ÓÃÕ߸¶·Ñ·¨°¸ ¡·(PDUFA)£¬¼ÓËÙFDAµÄÉó²éʱ¼ä

?

ng28ÄϹ¬ÓÚ²³½¡½ñÈÕÐû²¼£¬ÃÀ¹úʳƷºÍÒ©ÎïÖÎÀí¾Ö(FDA)ÒѽÓÊÜng28ÄϹ¬100mg /mL×¢ÉäÒºLEQEMBI?(lecanemab-irmb)Ôö²¹ÉúÎïÖƼÁÐí¿ÉÉêÇë(sBLA)£¬ÓÃÓÚ¾²Âö×¢É䣬ÒÔÖ§³ÖLEQEMBI¼ÓËÙÉóÅúÏò¹Å°åÉóÅúµÄת±ä¡£LEQEMBI?ÉêÇëÒÑ»ñµÃÓÅÏÈÉóÆÀ×ʸñ£¬´¦·½Ò©Óû§ÊÕ·Ñ·¨°¸(PDUFA)µÄÉúЧÈÕÆÚΪ2023Äê7ÔÂ6ÈÕ¡£FDAÄ¿Ç°Õý¼Æ»®ÕÙ¿ª×ÉѯίԱ»áÌÖÂÛ¸ÃÉêÇ룬µ«ÉÐδ¹ûÕæÐû²¼¼¯»áÈÕÆÚ¡£

LEQEMBI?ÊÇÒ»ÖÖÕë¶Ô¾Û¼¯¿ÉÈÜÐÔ(¡°Ô­ÏËά¡±)ºÍ²»ÈÜÐÔµí·ÛÑùÂѰצ£¨A¦Â£©ÐÎʽµÄÈËÔ´»¯ÃâÒßÇòÂѰצÃ1£¨IgG1£©µ¥¿Ë¡¿¹Ì壬ÓÚ2023Äê1ÔÂ6ÈÕFDAÔÚ¿ìËÙͨµÀÈ϶¨ÏÂÅú×¼ÓÃÓÚÖÎÁÆ°¢¶û´Äº£Ä¬²¡(AD)¡£LEQEMBI?½öÊÊÓÃÓÚÖÎÁÆÇá¶ÈÈÏÖªÕÏ°­»ò´¦ÓÚÇá¶È³Õ´ôÆÚ²¢Ö¤Êµ±£´æA¦Â²¡ÀíµÄ»¼Õß¡£ÔÚLEQEMBI?»ñµÃÅú×¼µ±Ì죬ng28ÄϹ¬½«Ñ¸ËÙÏòFDAÌá½»Ôö²¹ÉúÎïÖƼÁÐí¿ÉÉêÇ루sBLA£©£¬ÒÔ±ãÔڹŰå;¾¶Ï½øÐÐÉóÅú¡£sBLAÊÇ»ùÓÚng28ÄϹ¬×î½üÐû²¼µÄ´óÐÍÈ«ÇòÑéÖ¤ÐÔIIIÆÚÁÙ´²ÊÔÑéClarity ADµÄÑо¿½á¹ûÀ´Ìá½»µÄ¡£LEQEMBI?Âú×ãÖ÷ÒªÖÕµãºÍËùÓÐÒªº¦´ÎÒªÖյ㣬½á¹û¾ßÓÐÏÔÖøͳ¼ÆѧÒâÒå¡£2022Äê11Ô£¬Clarity ADÑо¿µÄ½á¹ûÔÚ°¢¶û´Äº£Ä¬²¡ÁÙ´²ÊÔÑé(CTAD)¼¯»áÉÏÐû²¼£¬²¢Í¬Ê±Ðû²¼ÔÚͬÐÐÆÀÉóµÄҽѧÔÓÖ¾¡¶ÐÂÓ¢¸ñÀ¼Ò½Ñ§ÔÓÖ¾¡·ÉÏ¡£

LEQEMBI?ÒÑÔÚÃÀ¹ú»ñµÃÅú×¼£¬²¢ÓÚ2023Äê1ÔÂ18ÈÕÔÚÃÀ¹úÍƳö¡£¸ÃÅú×¼ÊÇ»ùÓÚIIÆÚÊý¾Ý£¬ÕâЩÊý¾Ý±êÃ÷LEQEMBI¼õÉÙÁËA¦Â°ß¿éÔÚ´óÄÔÖеĻýÀÛ£¬ÕâÊÇADµÄÒ»¸ö¾ö¶¨ÐÔÌØÕ÷£¬Æä¼ÌÐøÅú×¼½«È¡¾öÓÚÔÚÑéÖ¤ÐÔÊÔÑéÖÐÑéÖ¤LEQEMBI?µÄÁÙ´²ÓÅÊÆ¡£FDAÒÑÈ·¶¨Clarity ADµÄ½á¹û¿É×÷ΪÑéÖ¤lecanemabÁÙ´²»ñÒæµÄÑéÖ¤ÐÔÑо¿¡£

LEQEMBI?µÄÈ«Çò¿ª·¢ºÍ¼à¹ÜÌá½»ÓÉng28ÄϹ¬Ö÷µ¼£¬¶ø²úÆ·ÔòÓÉng28ÄϹ¬ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍƹã¡£ÆäÖУ¬ng28ÄϹ¬ÓµÓÐ×îÖÕ¾ö²ßȨ¡£

 

Contacts
Eisai

MEDIA CONTACT:

Eisai Co., Ltd.

Public Relations Department

TEL: +81 (0)3-3817-5120

 

Eisai Inc. (U.S.)

Libby Holman

+ 1-201-753-1945

Libby_Holman@eisai.com

 

Eisai Europe, Ltd.

(UK, Europe, Australia, New Zealand and Russia)

EMEA Communications Department

+44 (0) 786 601 1272

EMEA-comms@eisai.net

 

INVESTOR CONTACT:

Eisai Co., Ltd.

Investor Relations Department

TEL: +81 (0) 3-3817-5122

Biogen Inc.

 

MEDIA CONTACT:

Natacha Gassenbach

+ 1-857-777-6573

 

public.affairs@biogen.com

 

INVESTOR CONTACT:

Mike Hencke

+ 1-781-464-2442

IR@biogen.com